Multisociety Consensus Endorses Beta-Lactam Dose Individualization in Acutely Ill Patients

Seven international societies now formally back concentration-guided beta-lactam dosing, positioning pharmacists to lead TDM and model-informed personalized dosing programs.

Beta-Lactam Dose Individualization Consensus GuidanceACCP/ESCMID/IDSA/SCCM/SIDPsepsis and acute illnessbeta-lactam antibioticsTDMMIPD Infectious Disease / Antimicrobials

Background Information

New guidelines urge personalized beta-lactam dosing for acutely ill patients.

Beta-lactam antibiotics are crucial in treating acutely ill patients, but standard dosing may not ensure optimal efficacy and safety. Consensus guidance recommends individualized beta-lactam dosing based on patient-specific serum concentrations, addressing variability in drug levels. The guideline emphasizes personalized dosing for beta-lactams in severe infections, improving treatment outcomes by tailoring therapy to individual patient needs. Individualizing beta-lactam doses enhances effectiveness and safety for critically ill patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Barreto EF, McCreary EK, Pai Mangalore R, Tang Girdwood S, Arriola R, Bens C, Bonomo RA, Edginton AN, Hong LT, Huttner A, Koch BCP, Maranchick N, Neely MN, Peloquin CR, Rao GG, Roberts JA, Röhr AC, Scheetz MH, Schuetz AN, Yarnold PR, Zuluaga A, Rhodes NJ

Citation: Barreto EF, McCreary EK, Pai Mangalore R, et al. Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti-Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2026;46(8):e70181. doi:10.1002/phar.70181

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →